Is it safe to use a proton pump inhibitor with clopidogrel?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 9, 2009, Pages 564-568

  Chow, Clara K ^a   Moayyedi, Paul ^b   Devereaux, Philip J ^b  

^a HAMILTON GENERAL HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Clopidogrel; Drug interaction; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR;

ACUTE CORONARY SYNDROME; CARDIAC PATIENT; CARDIOVASCULAR MALFORMATION; CORONARY STENT; DIGESTIVE SYSTEM ULCER; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG USE; DUODENUM ULCER; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART PROTECTION; HUMAN; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; LOW DRUG DOSE; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STOMACH PH; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT INDICATION; UPPER GASTROINTESTINAL BLEEDING;

EID: 70349862968     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.767     Document Type: Review

References (25)

1. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494-502. (Pubitemid 32758501)
2. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk? Aliment Pharmacol Ther. 2006; 24: 897-908.
3. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005; 352: 238-244. (Pubitemid 40110812)
4. Kallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006; 333: 726. (Pubitemid 44555169)
5. Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007; 11: iii-iv, 1-164. (Pubitemid 351209260)
6. Rostom A, Wells G, Tugwell P, et al. The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration meta-analysis of randomized controlled trials. J Rheumatol. 2000; 27: 2203-2214. (Pubitemid 30701091)
7. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007; 102: 507-515. (Pubitemid 46328156)
8. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008; 118: 1894-1909.
9. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv. 2003; 59: 295-302. (Pubitemid 36792384)
10. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006; 108: 2244-2247. (Pubitemid 44497506)
11. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008; 51: 1925-1934. (Pubitemid 351636443)
12. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel. Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes. Circulation. 2009; 119: 2553-2560.
13. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004; 109: 3171-3175.
14. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy. 2003; 23: 460-471. (Pubitemid 36384325)
15. Ishizaki T, Horai Y. : cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther. 1999; 13 Suppl 3: 27-36.
16. Gilard M, Arnaud B, Le Gal G, et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006; 4: 2508-2509. (Pubitemid 44575451)
17. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008; 51: 256-260.
18. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180: 713-718.
19. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008; 52: 1038-1039.
20. Aubert RE, Epstein RS, Teagarden JR, et al. Abstract 3998: Proton Pump Inhibitors Effect on Clopidogrel Effectiveness: The Clopidogrel Medco Outcomes Study. Circulation. 2008; 118: S-815.
21. Dunn SP, Macaulay TE, Brennan DM, et al. Abstract 3999: Baseline Proton Pump Inhibitor Use is Associated with Increased Cardiovascular Events With and Without the Use of Clopidogrel in the CREDO Trial. Circulation. 2008; 118: S-815.
22. Serebruany V, Goto S. Clopidogrel and proton pump inhibitors: Gastric protection at expense of vascular benefit? Thromb Haemost. 2009; 101: 607-609.
23. Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004; 32: 821-827. (Pubitemid 38955611)
24. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009; 101: 714-719.
25. Moayyedi P, Sadowski DC. Proton pump inhibitors and clopidogrel - hazardous drug interaction or hazardous interpretation of data? Can J Gastroenterol. 2009; 23: 251-252.